Key result
Off-label tirzepatide shows no reported cardiorenal biomarker effects in type 1 diabetes.
Why the study?
Does tirzepatide improve cardiovascular and renal biomarkers in overweight and obese adults with type 1 diabetes?
Observational
Does tirzepatide improve cardiovascular and renal biomarkers in overweight and obese adults with type 1 diabetes?
Answers are grounded in this paper and cite their sources.
Introduction: Overweight (OW) and obesity (OB) affect nearly two thirds of adults with type 1 diabetes (T1D), contributing to suboptimal glucose control, cardiovascular disease (CVD), and diabetic kidney disease (DKD). Many newer drugs such as tirzepatide (a dual-incretin) and sodium–glucose cotransporter-2 inhibitors are approved for people with type 2 diabetes associated with CVD and DKD. We evaluated CVD and DKD biomarkers with off-label long-term (21 months) use of tirzepatide in OW/OB adults with T1D.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2025) conducted an observational in Type 1 diabetes with overweight or obesity. Tirzepatide was evaluated on Cardiovascular and renal biomarkers. Off-label use of tirzepatide for 21 months was evaluated for its effect on cardiovascular and renal biomarkers in overweight and obese adults with type 1 diabetes, but results are not reported.
Synapse has enriched 10 related papers. Consider them for comparative context: